Patients with COVID-19 pneumonia may present with 2 distinct phenotypes, each warranting distinct treatments.
Among college students, human adenoviruses should be considered as a cause for respiratory illness.
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
Linezolid use in combination therapy is effective and as safe as other firstline treatments for moderate to severe nocardiosis.
A patient with a history of pulmonary paracoccidioidomycosis presented with relapsed disease in the central nervous system four years after initial treatment.
A parsimonious score system that accurately identified elderly and non-elderly patients with pneumonia at highest risk for mortality in the intensive care unit has been developed.
The incidence of developing tuberculosis is high among exposed infants and young children.
The FDA has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs (NSAIDS) in patients with coronavirus disease 2019 (COVID-19).
A phase 1 clinical trial evaluating an investigational vaccine for protection against coronavirus disease 2019 (COVID-19) has been initiated at the Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.
The FDA has issued an Emergency Use Authorization to Thermo Fisher for its TaqPath COVID-19 Combo Kit, a diagnostic test that detects nucleic acid from SARS-CoV-2, the virus that causes coronavirus disease 2019.
Vice President Mike Pence told reporters millions of much-needed testing kits for COVID-19 are on the way to clinics and labs nationwide.
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
We spoke with the founding director of the Center for Pulmonary Infection Research and Treatment, Charles Dela Cruz, MD, PhD, of Yale University to get a better understanding of the risks that COVID-19 may pose to patients with chronic lung disease.
Warning letters issued by the FDA and the Federal Trade Commission (FTC) have been sent to several companies selling fraudulent products claiming to treat or prevent coronavirus 2019 (COVID-19).
The COPD Foundation released practical recommendations for patients living with COPD who may have concerns about COVID-19.
Anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy in addition to standard pneumonia therapy does not improve mortality.
The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019 (COVID-19), expanding the criteria to a wider group of symptomatic patients.
Highly effective contact tracing and isolation may be viable containment strategies for a COVID-19.
More respirators, including certain N95 masks, will be made available to healthcare personnel, according to the FDA and the CDC.
A short, 9-month regimen of normal dose moxifloxacin maintained good effectiveness up to 24 months after therapy cessation in patients with rifampicin-resistant tuberculosis.